29958-14-3

Basic information

• Product Name: 2-ACETAMIDO-5-AMINOPYRIDINE
• Synonyms: 2-ACETAMIDO-5-AMINOPYRIDINE;5-Amino-2-acetamidopyridine;2-ACETAMIDO-5-AMINOPYRIDINE 98%;2-Acetamido-5-aminopyridine ,98%;N-(5-Amino-2-pyridyl)acetamide;N-(5-aminopyridin-2-yl)acetamide;AcetaMide, N-(5-aMino-2-pyridinyl)-;2-Acetamido-5-aminopyridine, 97.5%
• CAS NO: 29958-14-3
• Molecular Formula: C₇H₉N₃O
• Molecular Weight: 151.17
• EINECS: -0
• Product Categories: Pyridine;Pyridines derivates;C7 and C8;Heterocyclic Building Blocks;Pyridines
• Mol File: 29958-14-3.mol
• Article Data: 13

Chemical Properties

• Melting Point: 154-158 °C(lit.)
• Boiling Point: 319.3 °C at 760 mmHg
• Flash Point: 146.9 °C
• Appearance: /
• Density: 1.28 g/cm³
• Vapor Pressure: 0.000342mmHg at 25°C
• Refractive Index: 1.646
• PKA: 13.44±0.70(Predicted)
• BRN: 128346
• CAS DataBase Reference: 2-ACETAMIDO-5-AMINOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ACETAMIDO-5-AMINOPYRIDINE(29958-14-3)
• EPA Substance Registry System: 2-ACETAMIDO-5-AMINOPYRIDINE(29958-14-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36-43
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 29958-14-3(Hazardous Substances Data)

Usage

Uses

2-Acetamido-5-Aminopyridine is used in preparation of bicyclic heteroaryl compounds as CRBN protein regulators.

InChI:InChI=1/C7H9N3O/c1-5(11)10-7-3-2-6(8)4-9-7/h2-4H,8H2,1H3,(H,9,10,11)

Upstream product

• 5093-64-1 2-acetamido-5-nitropyridine 
• 67-56-1 methanol 
• 4214-76-0 5-nitro-pyridin-2-ylamine 

Downstream Products

• 1103232-26-3 N-(6-acetylaminopyridin-3-yl)-2,6-difluoro-3-(propane-1-sulfonylamino)benzamide 
• 17103-45-6 sulfanilic acid-(6-amino-[3]pyridylamide) 
• 1131595-37-3 N-(5-(trifluoromethyl)pyridin-2-yl)acetamide 
• 1356226-88-4 N-{5-[4-(3-cyano-4-fluorophenyl)pyrimidin-2-ylamino]pyridin-2-yl}acetamide 
• 769912-56-3 C₇H₁₀N₄O 
• 1008775-61-8 phenyl (6-acetamidopyridin-3-yl)carbamate 

Relevant articles and documents

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Chemoselective hydrogenation of functionalized nitroarenes using MOF-derived co-based catalysts

The synthesis, characterization, and application of nitrogen-doped carbon supported Co catalysts in selective hydrogenation of nitroarenes are described. The cobalt-based catalysts are prepared by simple pyrolysis of ZIF-67, a typical MOF material, under inert atmosphere. Physicochemical properties of the Co/C-N catalysts have been investigated by X-ray diffraction, elemental analysis, atomic absorption spectroscopy, scanning electron microscopy, transmission electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy. The Co-based materials were found to be highly efficient in the chemoselective hydrogenation of nitroarenes. A broad range of substituted nitroarenes are converted to the corresponding anilines in excellent yields under industrially viable conditions with other reducing groups remaining intact. In situ ATR-IR and XPS characterizations reveal that the Co-N centers present in the catalyst favor the preferential adsorption of nitro groups, leading to this unique chemoselectivity. The kinetic parameters of 4-nitrostyrene hydrogenation over the Co/C-N catalyst were investigated.

QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION

Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.